by John Conrad | Apr 3, 2026 | Policy News
Statement from John Conrad, President & CEO, iBIO “In Illinois, we’ve seen what the right environment can deliver — with recent investments from AbbVie and CSL Behring reinforcing our state’s role as a leader in biomanufacturing and innovation. And candidly, we’d...
by John Conrad | Oct 16, 2024 | iBIO News
In the heart of the Midwest, a technological revolution is brewing that could transform the landscape of pharmaceutical research. Chicago, long known for its towering skyscrapers and deep-dish pizza, is now poised to become the epicenter of a quantum-powered...
by John Conrad | Jun 14, 2024 | iBIO News
From John: The news coverage of the BioPharma industry has been a study in contrasts. As I compile the daily NewsBrief, I come across numerous articles highlighting companies, both large and small, that are compelled to reduce their workforce due to insufficient...
by John Conrad | Jun 13, 2024 | NewsBrief
Meitheal Pharmaceuticals, a Chicago-based pharmaceutical company, has been named the second fastest growing company on Crain’s Fast 50 list. The company recorded an impressive 13,294.6% growth rate, with over $230 million in revenue and a total of 90 employees,...
by John Conrad | Jun 6, 2024 | NewsBrief
The biopharma sector has undergone significant changes in venture funding and investment trends during the first quarter of 2024, according to a recent PitchBook report. Despite a decrease in deal count, the sector saw an increase in venture funding, with $7.4 billion...
